文献速递前列腺癌

前列腺癌筛查PSA检测:Cochrane系统评价简版

The PSA test for prostate cancer screening: an abridged Cochrane review.
PubMed 文献 · BJU Int · 2026-10-01

基于ERSPC的敏感性分析,筛查可能降低前列腺癌特异性死亡率(RR 0.87,95%CI 0.80-0.95;中等确定性),对总体死亡率可能无影响或影响很小(RR 0.99,95%CI 0.97-1.00;低确定性)。联合筛查(kallikrein panel+MRI)对检出率可能无影响,死亡率数据尚不成熟。

要点

  • PSA筛查可能降低前列腺癌特异性死亡率,但绝对获益小(每1000人减少2例死亡)。
  • 筛查对总体死亡率的影响不确定,证据确定性低。
  • 联合kallikrein panel和MRI的筛查对前列腺癌检出率可能无影响,死亡率数据未成熟。

核心结论

  • 前列腺癌筛查可能降低前列腺癌特异性死亡率,并可能降低总体死亡率。
  • 筛查对不良事件(以干预相关死亡率衡量)可能几乎无影响。
  • 研究局限性、不一致性和不精确性降低了效应估计的置信度,且结果对最小临床重要差异(MCID)的选择高度敏感。
  • 新兴替代方案(kallikrein panel联合MRI筛查)对前列腺癌诊断可能几乎无影响,但死亡率结果尚不明确。

研究设计与样本

  • 纳入随机对照试验(RCT),比较前列腺癌筛查与不筛查。
  • 采用标准Cochrane方法,使用GRADE方法评级证据确定性。

主要发现

  • 假设基线风险为每1000人16例前列腺癌相关死亡,相当于每1000人减少2例死亡(95%CI减少3例至减少1例)。
  • 假设基线风险为每1000人491例全因死亡,相当于每1000人减少5例死亡(95%CI减少15例至减少0例)。
  • 筛查对不良事件可能几乎无影响(RR 1.32,95%CI 0.48-3.65;低确定性)或生活质量。

关键数值与推荐

  • 前列腺癌特异性死亡率:RR 0.87(95%CI 0.80-0.95),基于ERSPC敏感性分析,中等确定性证据。
  • 总体死亡率:RR 0.99(95%CI 0.97-1.00),基于所有合格试验分析,低确定性证据。
  • 不良事件:RR 1.32(95%CI 0.48-3.65),低确定性证据。
  • ProScreen试验联合筛查:总体检出RR 1.85(95%CI 1.56-2.19),局限性检出RR 1.88(95%CI 1.55-2.27),晚期检出RR 1.78(95%CI 1.19-2.66),均为中等确定性证据。

临床怎么用

  • 临床决策应权衡PSA筛查的微小绝对获益与潜在危害,并考虑患者偏好。
  • 应与患者讨论筛查对前列腺癌特异性死亡率的可能降低作用及总体死亡率的不确定性。
  • 对于新兴联合筛查方案(kallikrein panel+MRI),应告知患者其对检出率可能无影响且死亡率证据尚不成熟。

局限性

  • 研究局限性、不一致性和不精确性降低了证据确定性。
  • 结果对最小临床重要差异(MCID)的选择高度敏感。
  • 联合筛查方案的死亡率数据尚不成熟。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess the effects of prostate cancer screening compared to no screening in men with no prior diagnosis of prostate cancer. METHODS: This systematic review represents an update of a prior Cochrane review from 2013, searching multiple databases up to November 2025. We included randomised controlled trials (RCTs) of prostate cancer screening vs no screening. We used standard Cochrane methods, including rating the certainty of the evidence following a Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach. RESULTS: Six RCTs (789 086 participants; follow-up 3.2-23 years) were included: five evaluated prostate-specific antigen (PSA)-alone screening; one evaluated PSA combined with a kallikrein panel and magnetic resonance imaging (MRI) (ProScreen). Results are based on the certainty of evidence for each outcome and are therefore mainly derived from a sensitivity analysis by risk of bias, using the European Randomised Study of Screening for Prostate Cancer (ERSPC) trial: screening likely results in a reduction in prostate cancer-specific mortality (sensitivity analysis from ERSPC: risk ratio [RR] 0.87, 95% confidence interval [CI] 0.80-0.95; one study, 162 236 participants; moderate-certainty evidence; minimal clinically important difference [MCID]: one per 1000 participants). Assuming a baseline risk of 16 prostate-cancer-related deaths per 1000, this corresponds to two fewer (95% CI three fewer to one fewer) per 1000. Based on the analysis that included all eligible trials, screening may reduce overall mortality, although the CI includes the possibility of little to no effect (RR 0.99, 95% CI 0.97-1.00; I2 = 22%; four studies, 675 121 participants; low-certainty evidence; MCID: one per 1000 participants). Assuming a baseline risk of 491 deaths from any cause per 1000, this corresponds to five fewer (95% CI 15 fewer to 0 fewer) per 1000. Screening may result in little to no difference in adverse events (RR 1.32, 95% CI 0.48-3.65; low certainty) or quality of life. In the ProScreen trial (60 745 participants, 3.2-year follow-up), combined screening probably has little to no effect on overall detection (RR 1.85, 95% CI 1.56-2.19; moderate certainty), localised detection (RR 1.88, 95% CI 1.55-2.27; moderate certainty), or advanced detection (RR 1.78, 95% CI 1.19-2.66; moderate certainty). Mortality data are not yet mature. CONCLUSIONS: Screening likely reduces prostate cancer-specific mortality and may reduce overall mortality. It may have little to no effect on adverse events (as measured by intervention-related mortality). Study limitations, inconsistency, and imprecision reduced our confidence in the effect estimates. Interpretation of these findings is highly sensitive to the choice of MCID. Emerging alternatives, such as screening with a kallikrein panel and MRI, may have little to no effect on diagnoses of prostate cancer, but the results on mortality are not yet known.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Franco JVA, Hwang EC, Jung JH, et al. The PSA test for prostate cancer screening: an abridged Cochrane review. BJU Int. 2026. PMID: 42820647. doi:10.1111/bju.70455

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。